NOVO-NORDISK A/S-SPONS ADR (NVO) Stock News

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm

Market Whales and Their Recent Bets on NVO Options

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025.

NVO INVESTOR ALERT: Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

/PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S (NYSE: NVO) securities between...

Stockholder Alert: Robbins LLP Informs Investors of the Novo Nordisk A/S Class Action

/PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Novo Nordisk A/S...

NVO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

Why Eli Lilly Stock Topped the Market Today

Why Novo Nordisk Stock Jumped a Lucky 7.7% Today

Novo Nordisk may have found a winner in amycretin.

Allurion Catapults 200% On Its Plans To Outdo Eli Lilly, Novo Nordisk

While the other companies are testing weight-loss drugs, Allurion has a different approach to obesity.

Novo Nordisk Stock Eyes Best Day In 17 Months On New Obesity Drug Trial Data: Retail Breathes Easy

The results also come as a relief following a selloff triggered by disappointing results from Novo’s CagriSema trial, which many deemed overblown.

Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results

The Danish drug giant reported a 22% weight loss over 36 weeks.

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing good growth, while it is not too expensive.

Is Novo Nordisk Stock a Buy?

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity. For the company to continue to grow at the same pace it has been recently, its blockbuster drugs, specifically its weight loss drug Wegovy, need to continue to retain a sizable share of the market.

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious

Though negotiated prices won't take effect until 2027, the inclusion of semaglutide has raised concerns about Novo's revenue and potential ripple effects on Eli Lilly's rival drugs.

Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts

The price negotiations will take place in 2025 and go into effect in 2027 for a new list of 15 drugs.

Novo’s Ozempic, Wegovy Targeted for Medicare Price Negotiations

The US will slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns.

Eli Lilly: What's Left To Like? A Lot, Says One Analyst.

The company cut its fourth-quarter guidance by 5%. But there's still a lot happening for Lilly.